JP6818348B2 - シスタチンaをマーカーとして用いる癌の検出 - Google Patents
シスタチンaをマーカーとして用いる癌の検出 Download PDFInfo
- Publication number
- JP6818348B2 JP6818348B2 JP2016254136A JP2016254136A JP6818348B2 JP 6818348 B2 JP6818348 B2 JP 6818348B2 JP 2016254136 A JP2016254136 A JP 2016254136A JP 2016254136 A JP2016254136 A JP 2016254136A JP 6818348 B2 JP6818348 B2 JP 6818348B2
- Authority
- JP
- Japan
- Prior art keywords
- cystatin
- cancer
- pancreatic cancer
- colorectal cancer
- concentration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 102000012193 Cystatin A Human genes 0.000 title claims description 30
- 108010061641 Cystatin A Proteins 0.000 title claims description 30
- 206010028980 Neoplasm Diseases 0.000 title description 10
- 201000011510 cancer Diseases 0.000 title description 8
- 238000001514 detection method Methods 0.000 title description 2
- 239000003550 marker Substances 0.000 title description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 29
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 29
- 201000002528 pancreatic cancer Diseases 0.000 claims description 29
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 29
- 206010009944 Colon cancer Diseases 0.000 claims description 27
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 23
- 238000000034 method Methods 0.000 claims description 22
- 210000004369 blood Anatomy 0.000 claims description 9
- 239000008280 blood Substances 0.000 claims description 9
- 238000002965 ELISA Methods 0.000 claims description 5
- 208000029742 colonic neoplasm Diseases 0.000 claims description 4
- 239000000523 sample Substances 0.000 description 11
- 210000002966 serum Anatomy 0.000 description 7
- 230000035945 sensitivity Effects 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 4
- 101000921786 Homo sapiens Cystatin-A Proteins 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 102000045247 human CSTA Human genes 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 238000003018 immunoassay Methods 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 239000012472 biological sample Substances 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 239000004816 latex Substances 0.000 description 2
- 229920000126 latex Polymers 0.000 description 2
- 239000000439 tumor marker Substances 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 210000004970 cd4 cell Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000003317 immunochromatography Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 229920000371 poly(diallyldimethylammonium chloride) polymer Polymers 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
Landscapes
- Peptides Or Proteins (AREA)
Description
[1] 被験体より採取した血液中のシスタチンAを測定することを含む、膵癌又は大腸癌を検出する方法。
[2] 被験体より採取した血液中のシスタチンAを測定することを含む、[1]の膵癌又は大腸癌を検出する方法。
[3] 被験体の血液中のシスタチンA濃度が健常人の血液中のシスタチンA濃度よりも高い場合に、被験体が膵癌又は大腸癌に罹患していると判断する、[1]又は[2]の膵癌又は大腸癌を検出する方法。
[4] [1]〜[3]のいずれかの膵癌又は大腸癌を検出する方法に用いる検査試薬であって、抗シスタチンA抗体を含む検査試薬。
本発明は、シスタチンA(Cystatin A)をマーカーとして用いて、膵癌又は大腸癌を検出する方法である。
シスタチンAは、生体内において、T細胞依存性腫瘍免疫を誘導し得る。該T細胞依存性腫瘍免疫はCD4細胞及びCD8細胞を介した腫瘍免疫である。
Claims (1)
- 被験体より採取した血液中のシスタチンAをELISAにて測定することを含む、膵癌又は大腸癌を検出するための補助的方法であって、血液中のシスタチンA濃度が0.31ng/mLより大きい場合に被験体は膵癌又は大腸癌に罹患していると検出する、補助的方法。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2016254136A JP6818348B2 (ja) | 2016-12-27 | 2016-12-27 | シスタチンaをマーカーとして用いる癌の検出 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2016254136A JP6818348B2 (ja) | 2016-12-27 | 2016-12-27 | シスタチンaをマーカーとして用いる癌の検出 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2018105790A JP2018105790A (ja) | 2018-07-05 |
JP6818348B2 true JP6818348B2 (ja) | 2021-01-20 |
Family
ID=62787858
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016254136A Active JP6818348B2 (ja) | 2016-12-27 | 2016-12-27 | シスタチンaをマーカーとして用いる癌の検出 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP6818348B2 (ja) |
-
2016
- 2016-12-27 JP JP2016254136A patent/JP6818348B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
JP2018105790A (ja) | 2018-07-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20220214344A1 (en) | Method, array and use thereof | |
KR101431062B1 (ko) | 유방암 진단용 다중 바이오마커 세트, 이의 검출 방법 및 이에 대한 항체를 포함하는 유방암 진단키트 | |
CN112362871B (zh) | 食管癌的生物标志物及其应用 | |
CN111273012B (zh) | 一种血清自身抗体联合检测的方法 | |
JPWO2019004430A1 (ja) | 大腸がんを検出するためのバイオマーカー | |
US20160195546A1 (en) | Type 1 Diabetes Biomarkers | |
JP2015105951A (ja) | 血液由来の癌診断用ペプチドマーカー及びそれを用いた癌診断方法 | |
EP3516399B1 (en) | Diagnosis of acute pancreatitis (ap) by detection of glycoprotein 2 isoform alpha (gp2a) | |
CN110716050A (zh) | 抗原组合在制备用于肺癌相关自身抗体检测的试剂盒中的用途以及相应的试剂盒和检测方法 | |
Nguyen et al. | Capillary electrophoresis-laser-induced fluorescence (CE-LIF)-based immunoassay for quantifying antibodies against cyclic citrullinated peptides | |
JP6639408B2 (ja) | デオキシハイプシン・シンターゼ遺伝子を指標として用いる動脈硬化及びがんの検出方法 | |
JP6818348B2 (ja) | シスタチンaをマーカーとして用いる癌の検出 | |
WO2006054806A1 (ja) | クローン病関連自己抗原 | |
CN115372616A (zh) | 胃癌相关的生物标志物及其应用 | |
KR101431067B1 (ko) | 유방암 진단용 단백질 마커 아포리포단백질 (a), 이의 검출 방법 및 이에 대한 항체를 포함하는 유방암 진단키트 | |
CN102300875A (zh) | 肾病相关的生物标记 | |
Benlier et al. | A novel diagnostic tool for the detection of bladder cancer: measurement of urinary high mobility group box-1 | |
Tan et al. | Utility of dominant epitopes derived from cell-wall protein LppZ for immunodiagnostic of pulmonary tuberculosis | |
Martín-Yerga et al. | Electrochemical immunosensors for celiac disease detection | |
CN110004220A (zh) | 一种银屑病血清标志物及其应用 | |
KR101989917B1 (ko) | 형광검출기가 장착된 모세관 전기영동을 이용한 류마티스 관절염 진단방법 | |
Narain | Identification and Clinical Validation of Novel Prostate Cancer Biomarkers Filamin A (flna), Filamin B (flnb), and Keratin 19 (krt19) Using Patient-Derived Omics and Bayesian Artificial Intelligence | |
JP2024060569A (ja) | 本態性高血圧症を検出するためのバイオマーカー、それを用いた検出方法及び検出試薬 | |
Kibat | Development of a protein microarray platform for the characterization of antibodies and quantitative immunoassays | |
WO2013186748A1 (en) | A method and a kit for the in vitro diagnosis of pancreatic ductal adenocarcinoma or for determining the predisposition to pancreatic ductal adenocarcinoma |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190719 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20200526 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200609 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200806 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20201006 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20201112 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20201208 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20201221 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6818348 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |